BioNTech continues to expect to report a loss ... Co., Ltd. (“MediLink”). BNT211 consists of a chimeric antigen receptor (“CAR”)-T cell product candidate targeting Claudin-6 (“CLDN6 ...

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) to report its financial ...

“BioNTech’s achievements during the period ... Cell Therapy Programs BNT211 consists of a chimeric antigen receptor (“CAR”)-T cell product candidate targeting Claudin-6 (“CLDN6 ...

“BioNTech’s achievements during the period ... where the safety profile was manageable and encouraging clinical activity was observed. Cell Therapy Programs BNT211 consists of a ...

BNT211 already has orphan drug and fast-track ... at approximately 35%. BioNTech and Regeneron are competing with rivals Moderna and MSD in the mRNA melanoma jab category, with the latter a ...

with BNT211 in solid tumors. While oncology is still central to BioNTech's pipeline, BioNTech's expert knowledge of mRNA easily lends itself to the development of vaccines for viral infections ...